+

WO2017196044A3 - Système et procédé de criblage d'agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes en utilisant les cellules tumorales circulantes du sang du patient atteint d'un cancer de la prostate - Google Patents

Système et procédé de criblage d'agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes en utilisant les cellules tumorales circulantes du sang du patient atteint d'un cancer de la prostate Download PDF

Info

Publication number
WO2017196044A3
WO2017196044A3 PCT/KR2017/004766 KR2017004766W WO2017196044A3 WO 2017196044 A3 WO2017196044 A3 WO 2017196044A3 KR 2017004766 W KR2017004766 W KR 2017004766W WO 2017196044 A3 WO2017196044 A3 WO 2017196044A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
prostate cancer
anticancer agent
androgen receptor
circulating tumor
Prior art date
Application number
PCT/KR2017/004766
Other languages
English (en)
Korean (ko)
Other versions
WO2017196044A2 (fr
Inventor
전병희
Original Assignee
주식회사 싸이토젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 싸이토젠 filed Critical 주식회사 싸이토젠
Publication of WO2017196044A2 publication Critical patent/WO2017196044A2/fr
Publication of WO2017196044A3 publication Critical patent/WO2017196044A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un système et un procédé de criblage d'un agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes, utilisant les cellules tumorales circulantes (CTC) d'un patient atteint du cancer de la prostate.
PCT/KR2017/004766 2016-05-09 2017-05-08 Système et procédé de criblage d'agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes en utilisant les cellules tumorales circulantes du sang du patient atteint d'un cancer de la prostate WO2017196044A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160056663A KR101876725B1 (ko) 2016-05-09 2016-05-09 전립선 암 환자의 혈중 순환 종양세포를 활용한 안드로겐 수용체 과발현 환자의 맞춤형 항암제 선별시스템 및 선별방법
KR10-2016-0056663 2016-05-09

Publications (2)

Publication Number Publication Date
WO2017196044A2 WO2017196044A2 (fr) 2017-11-16
WO2017196044A3 true WO2017196044A3 (fr) 2018-08-02

Family

ID=60267756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004766 WO2017196044A2 (fr) 2016-05-09 2017-05-08 Système et procédé de criblage d'agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes en utilisant les cellules tumorales circulantes du sang du patient atteint d'un cancer de la prostate

Country Status (2)

Country Link
KR (1) KR101876725B1 (fr)
WO (1) WO2017196044A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129676A1 (en) * 1998-02-12 2003-07-10 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2006041453A1 (fr) * 2004-09-30 2006-04-20 Immunivest Corporation Cellules tumorales circulantes (ctc): evaluation de l'apoptose chez les patients presentant un cancer de la prostate
WO2007089911A2 (fr) * 2006-01-30 2007-08-09 The Scripps Research Institute procedes de detection de cellules tumorales circulantes et procedes de diagnostic de cancer chez un sujet mammalien

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101275744B1 (ko) * 2010-10-25 2013-06-14 주식회사 싸이토젠 금속 스크린필터

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129676A1 (en) * 1998-02-12 2003-07-10 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2006041453A1 (fr) * 2004-09-30 2006-04-20 Immunivest Corporation Cellules tumorales circulantes (ctc): evaluation de l'apoptose chez les patients presentant un cancer de la prostate
WO2007089911A2 (fr) * 2006-01-30 2007-08-09 The Scripps Research Institute procedes de detection de cellules tumorales circulantes et procedes de diagnostic de cancer chez un sujet mammalien

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAGBANUA: "Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer", BMC CANCER, vol. 12, no. 78, 2012, pages 1 - 12, XP021095001 *
REYES: "Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 12, no. 313, 2014, pages 1 - 15, XP021206180 *

Also Published As

Publication number Publication date
KR101876725B1 (ko) 2018-07-13
KR20170126350A (ko) 2017-11-17
WO2017196044A2 (fr) 2017-11-16

Similar Documents

Publication Publication Date Title
EP4338799A3 (fr) Lymphocytes infiltrant les tumeurs et procédés de thérapie
MX2022001718A (es) Combinaciones de cabozantinib y atezolizumab para tratar cancer.
WO2014018563A3 (fr) Procédés pour le traitement du cancer
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
SG10202111808WA (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
IL280760A (en) Pharma
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
EP4302784A3 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3683321A3 (fr) Procédés relatifs à des groupes de cellules tumorales circulantes et au traitement du cancer
EP3684420A4 (fr) Méthodes de traitement du cancer du sein triple négatif
WO2014134084A3 (fr) Compositions de phf20 et jmjd3 et méthodes d'utilisation pour l'immunothérapie anticancéreuse
SG10201903658QA (en) Personalized anti-cancer agent screening system
WO2019035565A3 (fr) Procédé de dépistage d'un patient atteint d'un cancer de la prostate basé sur un variant de récepteur d'androgènes
WO2014172608A3 (fr) Dérivés de parthénolide et modulation par ceux-ci de processus commandés par translation régulée
EP3548088A4 (fr) Thérapie pour le cancer urothélial métastatique avec le conjugué anticorps-médicament, sacituzumab govitécan (immu-132)
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
NZ726050A (en) Modulators of androgen synthesis
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2017181163A3 (fr) Méthodes et compositions pour la détection et le diagnostic du cancer du sein
WO2015015301A3 (fr) Thérapie anticancéreuse avec des nanoparticules d'argent
EP3303363A4 (fr) Hétérogénéité génomique intra-patients de cellules tumorales circulantes (ctc) uniques associée à l'hétérogénéité de ctc phénotypique dans le cancer de la prostate métastasique androgéno-indépendant (mcrpc)
WO2019030757A8 (fr) Récepteur d'antigène chimérique pour her2/neu et lymphocytes t l'exprimant
WO2014087240A3 (fr) Compositions, procédés et coffrets de prévention, de réduction et d'élimination de métastase de cancer
PH12017502011A1 (en) Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
WO2017196044A3 (fr) Système et procédé de criblage d'agent anticancéreux personnalisé pour un patient présentant une surexpression du récepteur des androgènes en utilisant les cellules tumorales circulantes du sang du patient atteint d'un cancer de la prostate

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17796344

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/03/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17796344

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载